Alliance for Pandemic Preparedness

October 20, 2020

Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial

Category:

Topic:

Keywords (Tags):

  • A randomized open-label trial of treatment with the immune modulator tocilizumab (TCZ) in patients with COVID-19 pneumonia found that the rate of clinical worsening (entry to ICU unit with intubation, death from all causes, or clinical aggravation) was not significantly different among patients receiving tocilizumab (TCZ) (n=60) and those receiving standard of care (n=66) (RR=1.05; 95%CI 0.59-1.86).
  • This trial was halted after an interim analysis for futility.

Salvarani et al. (Oct 20, 2020). Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2020.6615